A Detailed Review on Sustained-Release Matrix Tablets: Formulation Strategies, Drug Release Mechanisms, and Future Perspectives in Oral Controlled Drug Delivery

Oral drug administration remains the most commonly preferred route due to its convenience, patient acceptability, and flexibility in dosage form development. The physiological characteristics of the gastrointestinal tract allow formulation scientists to design a wide range of drug delivery systems with varying release profiles. Sustained-release and other modified-release dosage forms—also referred to as prolonged-release, extended-release, or depot formulations—are specifically developed to provide a continuous and controlled release of the drug over an extended duration following a single administration.[1] Delivering medication in a single dose that releases the drug gradually offers several advantages over conventional multiple-dose regimens. Maintaining relatively constant plasma drug concentrations can improve therapeutic effectiveness while minimizing fluctuations that may lead to adverse effects. Additionally, reduced dosing frequency enhances patient compliance, which is a critical factor in successful long-term therapy.[2] The rising cost, complexity, and time associated with the development and approval of new chemical entities have shifted pharmaceutical research toward optimizing existing drugs through advanced drug delivery technologies. Among these approaches, sustained-release systems have gained significant importance. Matrix-based delivery systems are one of the most widely used strategies for achieving sustained drug release. In such systems, the drug is uniformly distributed within a polymeric matrix, typically composed of hydrophilic gelling agents, which regulate drug release through diffusion and matrix erosion mechanisms.[3] The primary objective of an extended-release dosage form is to maintain effective plasma drug concentrations over a prolonged period, thereby improving therapeutic outcomes and patient adherence to treatment.[4]. Commonly used matrix formers include hydrophilic polymers such as hydroxypropyl methylcellulose (HPMC), sodium alginate, xanthan gum, and natural gums, as well as hydrophobic polymers like ethyl cellulose and waxes. [5] Design of Experiments (DoE) has emerged as a powerful and indispensable tool in pharmaceutical research and development. DoE is a structured, multivariate statistical methodology that enables simultaneous evaluation of multiple formulation and process factors and their interactions on critical quality attributes (CQAs) of the dosage form.[6]

Limitations of Conventional Dosage Forms

Conventional dosage forms are associated with several significant limitations. Frequent dosing is often required for drugs with short biological half-lives, which can reduce patient adherence and increase the likelihood of missed doses. Additionally, these dosage forms commonly produce wide variations in plasma drug concentrations, resulting in periods of sub therapeutic or excessive drug levels. Such systems typically generate a pronounced peak–trough pattern in the plasma concentration–time profile, making it difficult to achieve and maintain steady-state drug levels. These fluctuations may increase the risk of adverse effects, particularly for drugs with a narrow therapeutic index, where even minor increases in concentration can lead to toxicity To address these shortcomings, substantial progress has been made in the field of advanced drug delivery systems. Modern delivery approaches are designed to regulate the rate of drug release, extend the duration of therapeutic action, and, in some cases, selectively target drug delivery to specific tissues or sites of action. These innovations aim to improve therapeutic efficacy, safety, and patient compliance compared to conventional dosage forms.[6]

Advantages of Sustained-Release Drug Delivery Systems

i) Improved patient compliance

Poor adherence to medication regimens is commonly observed in chronic conditions that require long-term therapy. The success of pharmacological treatment largely depends on a patient’s ability and willingness to follow the prescribed dosing schedule. Compliance may be influenced by several factors, including awareness of the disease, confidence in the treatment, complexity of the dosing regimen, treatment cost, and the occurrence of local or systemic side effects. Sustained-release drug delivery systems help overcome these challenges by reducing dosing frequency, thereby improving patient convenience and adherence to therapy.

ii) Reduction in plasma concentration fluctuations

Conventional dosage forms often produce marked fluctuations in drug concentration within systemic circulation and target tissues, resulting in a characteristic peak-and-trough or “see-saw” pattern. The extent of these variations is influenced by pharmacokinetic parameters such as absorption rate, distribution, elimination, and dosing intervals. These fluctuations are especially pronounced for drugs with short biological half-lives, typically less than four hours, where frequent dosing is required. Properly designed sustained-release formulations minimize such variations by maintaining more consistent drug levels over time.

iii) Decrease in total drug dose

Sustained-release systems often require a lower overall amount of drug to achieve the desired therapeutic effect. By maintaining effective plasma concentrations for extended periods, these formulations reduce the need for repeated dosing. As a result, the incidence of both systemic and localized adverse effects may be decreased, while also contributing to cost efficiency in drug therapy.

iv) Enhanced therapeutic effectiveness

Effective disease management depends on delivering adequate drug concentrations to the intended target tissues. Conventional dosage forms may require administration of higher doses to compensate for rapid drug elimination or poor bioavailability, which can lead to unwanted toxic or immunological responses in non-target tissues. Sustained-release dosage forms provide controlled drug delivery, enabling better therapeutic control in both acute and chronic conditions while minimizing undesirable side effects.

v) Cost effectiveness

Although sustained-release formulations often have a higher initial manufacturing cost compared to conventional dosage forms, the overall cost of therapy may be reduced over long-term treatment. This reduction is attributed to decreased dosing frequency, improved patient compliance, reduced side effects, and fewer treatment failures, making sustained-release systems economically beneficial in prolonged therapy.[5][7][8]

Figure 1: Plasma drug concentration time profile

Matrix Tablets

Matrix tablets are a type of oral controlled or extended-release dosage form in which the active pharmaceutical ingredient (API) is uniformly distributed within a mixture of active and inactive components. This system is widely used in extended-release drug delivery because of its simple manufacturing process, cost-effectiveness, and ability to maintain a controlled drug release profile. Drug release from matrix systems mainly follows Fick’s first law of diffusion, which describes the movement of drug molecules from a region of higher concentration to a lower concentration.

In a matrix tablet, the drug is present as solid particles embedded within a porous polymeric network. The matrix may be composed of hydrophobic polymers such as wax, polyethylene, polypropylene, or ethyl cellulose, or hydrophilic polymers like hydroxypropyl cellulose, hydroxypropyl methylcellulose (HPMC), methylcellulose, sodium carboxymethylcellulose, alginates, and scleroglucan. The term matrix refers to the three-dimensional structure formed by these polymers that entraps the drug along with other formulation components such as excipients and solvents.

Matrix drug delivery systems provide a continuous and sustained release of the drug. Drug release occurs through a combination of diffusion and dissolution mechanisms. At the initial stage, drug particles located on or near the surface of the tablet dissolve quickly, resulting in a relatively rapid release. After this phase, the drug located deeper within the matrix gradually dissolves and diffuses through the pores of the polymeric network to the external environment, leading to sustained drug release over time.

In these systems, the drug reservoir is created by uniformly dispersing drug particles within a rate-controlling polymer matrix, which may be hydrophilic or lipophilic in nature. Several methods can be used to prepare matrix tablets. One approach involves mixing finely powdered drug with a liquid or highly viscous polymer, followed by cross-linking of polymer chains. Another method includes blending the drug with polymer at elevated temperatures to ensure uniform dispersion. Alternatively, both drug and polymer may be dissolved in a common solvent, after which the solvent is removed by evaporation under heat or vacuum conditions to form the matrix structure.

The rate of drug release from diffusion-controlled matrix systems is time dependent and can be expressed at steady state by the following relationship:

[Q/t1/2 = (2ACRDp)1/2]

Where:

• A = Initial drug loading in the polymer matrix
• CR = Drug concentration in the reservoir system
• Dp = Diffusion coefficient of the drug within the polymer matrix

Drug release from matrix tablets can be regulated by adjusting several formulation factors, including drug loading, polymer characteristics, drug solubility in the polymer matrix, diffusivity of the drug molecules, and the porosity of the matrix system.[9]

Figure 2: Matrix tablets

Types of Matrix Formulations

Matrix formulations are drug delivery systems in which the active pharmaceutical ingredient is uniformly incorporated within an insoluble or slowly dissolving excipient matrix. In these systems, drug release occurs gradually through continuous diffusion or leaching of the drug from the inert matrix structure. This approach allows controlled and sustained drug delivery over an extended period.

Matrix systems are generally classified into three main categories:

1. Monolithic matrix tablets
2. Gel-forming hydrophilic matrix tablets
3. Erodible (hydrophobic) matrix tablets

Inert Monolithic Matrix Tablets

One of the simplest techniques for achieving sustained drug release in oral dosage forms is the incorporation of the drug into an inert matrix system. In this context, the term inert indicates that the matrix materials do not significantly interact with gastrointestinal fluids. These systems are widely used because the drug release profile is relatively independent of variations in gastrointestinal conditions, such as differences in pH, viscosity, or digestive fluid composition, which may vary between individuals. During passage through the gastrointestinal tract, the porous matrix tablet does not disintegrate like conventional tablets. Instead, the structure largely remains intact while the drug gradually diffuses out of the matrix. After complete drug release, the remaining polymeric framework or tablet skeleton may sometimes be excreted in the feces. The matrices used in these formulations are primarily composed of insoluble polymers or lipophilic substances. Early matrix systems utilized semi-synthetic or synthetic polymers such as polyethylene, polyvinyl chloride, polymethyl methacrylate, polystyrene, polyvinyl acetate, cellulose acetate, and ethyl cellulose. In addition, several hydrophobic materials including carnauba wax, hydrogenated castor oil, and tristearin have been used as matrix-forming agents. Despite their advantages, inert polymeric matrix tablets have certain limitations. A common drawback is their first-order drug release pattern, where the release rate decreases over time as the drug concentration within the matrix declines. Furthermore, these systems often exhibit poor direct compression properties, which may complicate tablet manufacturing. Another challenge involves equipment cleaning, especially when agglomeration processes are used to improve compressibility, as residual polymeric materials may adhere to processing equipment.

Mechanism of Drug Release from Inert Monolithic Matrix Tablets

Drug release from inert monolithic matrix tablets mainly occurs through a leaching and diffusion process. In this system, drug particles are uniformly dispersed within a polymeric matrix. When the tablet comes in contact with gastrointestinal fluids, the fluid penetrates into the porous structure of the matrix and dissolves the drug particles. The dissolved drug then diffuses outward through the interconnected pores of the matrix. These pores may already exist within the polymer network or may be formed as the embedded drug particles dissolve. When the drug loading in the matrix exceeds approximately 10–15% by volume, the drug particles form a continuous interconnected structure known as a percolation network. This network allows gastrointestinal fluid to reach most of the drug particles, resulting in efficient drug release. However, when the drug concentration in the matrix is much lower, some drug particles may remain completely surrounded by the polymer material. These trapped particles are unable to come in contact with the penetrating fluid, which may lead to incomplete drug release.

Solvent-Activated Matrix Tablets

Solvent-activated matrix tablets represent another approach for achieving controlled drug release, and the concept was first introduced by Hoffenberg as a means of obtaining near zero-order drug release, meaning a constant release rate over a prolonged period. In solvent-activated systems, drug release is controlled by the interaction between the polymer and the surrounding aqueous environment. When the dosage form is exposed to gastrointestinal fluids, several physicochemical processes may occur within the polymer matrix, including plasticization, swelling, dissolution, erosion, or degradation of the polymer structure. These changes regulate the rate at which the drug is released from the system. Two major categories of solvent-activated matrix tablets include:

1. Gel-forming hydrophilic matrix tablets
2. Erodible (hydrophobic) matrix tablets

Gel-Forming Hydrophilic Matrix Tablets

Gel-forming hydrophilic matrix systems, also known as swellable matrix systems, contain drug particles dispersed within a hydrophilic polymer that has the ability to absorb water and swell. These systems may be either homogeneous or heterogeneous depending on the distribution of the drug within the polymer matrix. Hydrophilic matrix tablets have been extensively investigated because they can potentially provide sustained and relatively constant drug release for extended periods. In such systems, the rate of drug release is strongly influenced by the physicochemical properties of the polymer, including its viscosity, swelling ability, and solubility. After oral administration, gastrointestinal fluids penetrate the tablet and interact with the hydrophilic polymer. This interaction causes plasticization of the polymer chains, leading to relaxation of the macromolecular structure and expansion of the matrix. As hydration progresses, a distinct boundary develops between the dry, glassy core of the tablet and the outer hydrated gel layer. The swollen gel layer acts as a barrier that controls drug release. Dissolved drug molecules diffuse through this gel layer into the surrounding medium. Initially, a burst release effect may occur because drug particles present at or near the surface dissolve rapidly before the protective gel barrier is fully established.[10][11]

Erodible Matrix Tablets

Erodible matrix tablets represent another approach for achieving controlled or near zero-order drug release. Certain biodegradable polymers, such as polyanhydrides, are commonly used in these systems. When these polymers come into contact with water or gastrointestinal fluids, they form a gel-like layer on the tablet surface. This hydrated layer gradually undergoes erosion at a predictable rate. By carefully selecting the polymer composition and formulation parameters, the thickness of the gel layer can remain relatively constant during the drug release process. As a result, the rate of polymer erosion and drug release can remain steady over time, allowing for continuous and controlled drug delivery until the drug content within the dosage form is depleted.[12]

Sustained-Release Oral Dosage Forms

Sustained-release dosage forms are designed to maintain therapeutic drug concentrations in the body for an extended period by releasing the drug gradually after administration. However, not every drug is suitable for formulation into a sustained-release system, and not every medical condition requires prolonged drug delivery. Therefore, both the physicochemical properties of the drug and the therapeutic requirements of the disease must be evaluated before developing a sustained-release formulation.

Drug Candidates Suitable for Sustained-Release Formulations

For a sustained-release dosage form to be effective, the drug must be released from the formulation at a controlled and predictable rate. After release, it should dissolve in gastrointestinal fluids, remain in the gastrointestinal tract for an adequate duration, and be absorbed efficiently so that the rate of drug absorption compensates for the rate of metabolism and elimination.

Generally, drugs that are most appropriate for sustained-release systems possess the following characteristics:

1. Moderate absorption and elimination rates

Drugs intended for sustained-release formulations should not have extremely slow or extremely rapid absorption and elimination. Drugs with naturally slow elimination rates often provide prolonged therapeutic effects on their own, making sustained-release formulations unnecessary. Conversely, drugs with very short biological half-lives (for example, less than about two hours) may require large quantities of drug in the dosage form, which can make sustained-release formulation impractical.

2. Consistent gastrointestinal absorption

Drugs incorporated into sustained-release dosage forms should be uniformly absorbed from the gastrointestinal tract. Adequate water solubility and sufficient residence time in the gastrointestinal tract are also important. Drugs that exhibit poor absorption or highly variable absorption patterns are generally unsuitable for sustained-release formulations because they may produce unpredictable therapeutic responses.

3. Small Dose Requirement

Drugs that are administered in relatively low doses are more appropriate for sustained-release formulations. If a drug requires a very large single dose, the size of the tablet or capsule needed to maintain prolonged therapeutic levels would become excessively large, making it difficult for patients to swallow. Therefore, drugs with high dose requirements are generally not ideal candidates for sustained-release dosage forms.

4. Adequate Safety Margin

Another important consideration is the safety margin of the drug, which is commonly expressed by its therapeutic index—the ratio between the median toxic dose and the effective therapeutic dose. Drugs with a larger therapeutic index are considered safer because there is a wider difference between the effective dose and the toxic dose. In contrast, highly potent drugs often have a narrow therapeutic index, meaning that small variations in drug concentration may lead to toxicity. Such drugs are usually unsuitable for sustained-release formulations due to the difficulty of maintaining precise control over the release rate and the potential risk of dose dumping caused by formulation defects.

5. Use in Chronic Conditions

Sustained-release drug delivery systems are generally more suitable for the management of chronic diseases, where long-term therapy is required to maintain stable drug levels in the body. In contrast, drugs used for acute conditions typically require rapid therapeutic action and frequent dose adjustments by physicians, making sustained-release formulations less appropriate for such situations.[13]

Over the past twenty years, controlled-release dosage forms have shown remarkable improvement in both therapeutic effectiveness and patient adherence to treatment. One of the simplest methods to achieve controlled drug delivery is the preparation of drug-loaded matrix tablets, which are produced by directly compressing a mixture of the drug, release-retarding agents, and other excipients. This approach allows the drug to be released gradually into the systemic circulation over a specific period.

Matrix systems are widely utilized in the production of controlled-release formulations because they simplify the manufacturing process. Various types of polymers are used as release-controlling agents, and each polymer contributes differently to the design and performance of the matrix system. The first group of retarding agents consists of insoluble polymers, often referred to as plastic or skeleton matrix systems. These materials remain intact in the dissolution medium and provide a rigid framework in which the drug is embedded.[14] The second category includes hydrophobic and water-insoluble substances that can gradually erode during drug release. These materials regulate drug release mainly through diffusion of the drug through pores and by slow erosion of the matrix structure.

The third category involves hydrophilic polymers, which form hydrophilic matrix systems. When these polymers come into contact with an aqueous environment, they do not immediately break apart. Instead, they absorb water and form a thick, gel-like layer on the tablet surface. This viscous gel barrier controls both the penetration of liquid into the tablet and the release of the drug from the matrix core.[15] Plastic matrix systems are commonly used because of their chemical stability and their ability to effectively entrap drug molecules. In such systems, the penetration of liquid into the matrix is often the rate-limiting step for drug release unless specific channeling agents are incorporated. In contrast, hydrophobic or wax-based matrices are capable of slow erosion and regulate drug release through a combination of pore diffusion and matrix erosion.

Among all controlled-release systems, hydrophilic matrices are the most frequently applied approach for oral drug delivery. Polymers such as hydroxypropyl methylcellulose (HPMC) have been extensively used since the early 1960s as rate-controlling agents in extended-release oral formulations. Hydrophilic matrix systems are considered highly versatile and widely accepted for controlled drug delivery. Several polysaccharide-based materials are employed in these systems, including cellulose derivatives like hydroxypropyl methylcellulose (HPMC) as well as other polymers such as sodium alginate, carrageenan, chitosan, and xanthan gum.[16][17]

Controlled Release Drug Delivery

Controlled release drug delivery systems have become an important part of modern pharmaceutical design. These systems improve drug effectiveness, safety, and reliability. Among different approaches, oral sustained-release formulations are widely used because they can maintain therapeutic drug levels for a longer period. Sustained-release tablets are designed to provide a uniform plasma drug concentration for up to 24 hours, which can also help improve bioavailability and reduce the effect of first-pass metabolism.[18]

The selected API belongs to BCS Class II, meaning it has low solubility and high permeability, making it suitable for sustained-release formulation. The drug shows approximately 20% oral bioavailability, so controlling the release rate can enhance its therapeutic performance.

Important Features of Sustained Release Tablets

• Reduced risk of dose dumping
• Lower inter- and intra-subject variability
• Uniform dispersion in the gastrointestinal tract
• Reproducible drug absorption and bioavailability
• Drug transport independent of gastric emptying

Advantages of Matrix Tablets[19][20]

• Simple and economical manufacturing process
• Capable of releasing drugs over a prolonged period
• Improves patient compliance by reducing dosing frequency
• Helps maintain steady therapeutic drug levels
• Reduces drug toxicity and side effects
• Protects drug from degradation in the gastrointestinal tract
• Can be prepared in different shapes and sizes
• Suitable for both biodegradable and non-biodegradable systems

Disadvantages of Matrix Tablets[19][20]

• Remaining matrix material may need to be eliminated after drug release
• Preparation may be costly in some cases
• Drug release may be influenced by food and gastrointestinal transit time
• Achieving perfect zero-order drug release is difficult
• Release rate gradually decreases over time
• Not all drugs are compatible with polymeric matrices

Terminology of Modified Release Drug Delivery Systems

The terms controlled release and sustained release are often used interchangeably, but they represent different drug delivery mechanisms. Sustained release (SR) systems are designed to release a drug slowly over an extended period, helping to maintain therapeutic drug levels. In contrast, controlled release (CR) systems deliver the drug at a predetermined and controlled rate for a prolonged duration.

• A modified release drug product refers to any formulation that alters the rate, timing, or location of drug release compared to conventional immediate-release dosage forms.
• Extended-release dosage forms are designed to reduce the dosing frequency, typically allowing at least a twofold reduction compared with immediate-release formulations. Examples include sustained-release, controlled-release, and long-acting dosage forms.
• Delayed-release dosage forms release the drug at a time other than immediately after administration. A common example is enteric-coated tablets, which release the drug after passing through the stomach.
• Targeted-release drug products are designed to deliver the drug at or near a specific physiological site of action. These formulations may exhibit either immediate or extended release characteristics.
• Repeat-action dosage forms release an initial dose of the drug followed by a second dose after a specific time interval.
• Prolonged-action dosage forms release the drug gradually to maintain therapeutic levels in the body for an extended duration.[21][22]

Classification of Matrix Tablets (Based on Retardant Material)[23-25]

Matrix tablets can be classified according to the type of retardant material used in the formulation.

1. Hydrophobic Matrix (Plastic Matrix): These matrices use inert or water-insoluble polymers to control drug release. The drug is mixed with hydrophobic materials and compressed into tablets. Drug release mainly occurs through diffusion of the dissolved drug through pores or channels formed within the polymer matrix. Common materials include polyethylene, ethyl cellulose, polyvinyl chloride, and acrylate polymers.[23]

2. Lipid Matrix: Lipid matrices are prepared using waxes and fatty substances. Drug release occurs through a combination of diffusion and matrix erosion, and it may be influenced by the composition of gastrointestinal fluids. Materials such as carnauba wax, stearyl alcohol, and stearic acid are commonly used.[24]

3. Hydrophilic Matrix: Hydrophilic polymer matrices are widely used in controlled drug delivery because they are flexible, economical, and well accepted by regulatory authorities. These systems form a gel layer when exposed to gastrointestinal fluids, which controls drug release. Polymers used include cellulose derivatives (HPMC, methylcellulose), natural polymers (agar, alginates, chitosan), and acrylic polymers such as carbopol.[25]

Fat–Wax Matrix Tablets: In these systems, the drug is incorporated into melted fats or waxes and then solidified to form granules. Drug release occurs through leaching, dissolution, or enzymatic degradation of the lipid material in the gastrointestinal tract. Surfactants may be added to modify the release rate.

4. Biodegradable Matrix: These matrices are made from polymers that can degrade naturally in the body through enzymatic or non-enzymatic processes. The polymers break down into smaller molecules that can be metabolized or excreted. Examples include proteins, polysaccharides, polyesters, and polyanhydrides.[26]

5. Mineral Matrix: Mineral matrices are prepared from naturally derived polymers, particularly those obtained from seaweeds. A common example is alginic acid, a hydrophilic carbohydrate extracted from brown seaweed.[27]

Polymers Used in Matrix Tablets[28]

Various polymers are used in matrix tablet formulations to control and sustain drug release. These polymers differ in their properties and mechanisms of action.

Hydrogels:

Hydrogels are water-swelling polymers that form a gel layer when in contact with biological fluids, helping to regulate drug release. Examples include poly(hydroxyethyl methacrylate) (PHEMA), cross-linked polyvinyl alcohol (PVA), cross-linked polyvinyl pyrrolidone (PVP), polyethylene oxide (PEO), and polyacrylamide.

Soluble Polymers:

These polymers dissolve gradually in aqueous environments and help control the release of the drug from the matrix system. Common examples are polyethylene glycol (PEG), polyvinyl alcohol (PVA), polyvinyl pyrrolidone (PVP), and hydroxypropyl methylcellulose (HPMC).

Biodegradable Polymers:

Biodegradable polymers break down in the body into smaller molecules that can be metabolized or eliminated. Examples include polylactic acid (PLA), polyglycolic acid (PGA), polycaprolactone (PCL), polyanhydrides, and polyorthoesters.

Non-Biodegradable Polymers:

These polymers remain stable in the biological environment and control drug release mainly through diffusion. Examples include polyethylene vinyl acetate, polydimethylsiloxane, polyether urethane, polyvinyl chloride, cellulose acetate, and ethyl cellulose.

Mucoadhesive Polymers:

Mucoadhesive polymers adhere to mucosal surfaces, which can prolong the residence time of the dosage form and enhance drug absorption. Examples include polycarbophil, sodium carboxymethyl cellulose, polyacrylic acid, tragacanth, methyl cellulose, and pectin.

Natural Gums:

Natural gums are widely used due to their biocompatibility and availability. Examples include xanthan gum, guar gum, karaya gum, and locust bean gum.

Methods of Preparation of Matrix Tablets

1. Wet Granulation Method:

In this method, the drug, polymer, and excipients are first mixed thoroughly. A binder solution is then prepared and added to form a wet mass. The wet mass is passed through a sieve to produce granules, which are dried and screened again to obtain uniform size. The dried granules are blended with lubricants and other additives before being compressed into tablets.

2. Dry Granulation Method:

In this technique, the drug, polymer, and excipients are mixed and then compressed into large tablets (slugs) or compacted using a roller compactor. The compacted material is milled and sieved to obtain granules. These granules are mixed with lubricants and finally compressed into tablets.

3. Sintering Method:

Sintering involves heating a compressed powder mass at a temperature below the melting point of its components. This process causes bonding between particles, which increases tablet hardness and can modify disintegration time. Sintering is used in sustained-release matrix tablets to enhance stability and slow down drug release.[29][30]

Mechanism of Drug Release from Matrix Tablets

Drug release from matrix tablets mainly occurs through diffusion and dissolution mechanisms. Initially, the drug present on the outer surface dissolves in the surrounding dissolution medium and diffuses out of the matrix. As the outer drug layer is depleted, the dissolution front gradually moves toward the inner part of the tablet. For diffusion-controlled systems, the dissolution of drug particles inside the matrix should be faster than the diffusion of the dissolved drug through the matrix.

The model describing drug release from a matrix system is based on certain assumptions such as:

• A pseudo-steady state is maintained during drug release.
• Drug particles are smaller than the diffusion path length in the matrix.
• The dissolution medium provides sink conditions throughout the process.

The release behavior can be described by the following equation:

[ dM/dh = Co. dh - Cs/2 ……………… (1)]

Where:

• dM = change in amount of drug released per unit area
• dh = change in thickness of the drug-depleted layer
• C? = initial drug concentration in the matrix
• C? = saturation solubility of the drug in the matrix

According to diffusion theory:

[dM = ( Dm. Cs / h) dt........................... (2)]

Where:

• D? = diffusion coefficient of drug in the matrix
• h = thickness of drug-depleted layer
• t = time

After integration, the relationship becomes:

[M = [Cs. Dm (2Co −Cs) t] ½ ……………… (3)]

When the drug concentration in the matrix is much higher than its solubility:

[M = [2Cs.Dm.Co.t] 1/2 ……………… (4)]

These equations show that drug release is proportional to the square root of time, which is characteristic of diffusion-controlled systems.

For porous matrix systems, drug release can be expressed as:

[M = [Ds. Ca. p/T. (2Co – p.Ca) t] 1/2…. (5)]

[M = [2D.Ca .Co (p/T) t] ½ …………….. (6)]

Where:

• p = porosity of matrix
• T = tortuosity (diffusion path)
• C? = solubility of drug in dissolution medium
• D? = diffusion coefficient in the medium

The total porosity of the matrix is given by:

[ p = pa + Ca/ ρ + Cex / ρex …………… (7)]

Where:

• p? = porosity due to air spaces
• ρ = density of drug
• ρ?? = density of excipients
• C?? = concentration of water-soluble excipients

For practical data analysis, the equation is simplified as:

[M = k. t 1/2 ……………………….. (8)]

Where k is a constant. A linear relationship between drug release and the square root of time indicates diffusion-controlled release from the matrix.

Drug release from matrix tablets can be controlled by factors such as initial drug concentration, matrix porosity, tortuosity, polymer type, and drug solubility.[31-34]

Designing Sustained-Release Drug Delivery Systems

In most orally administered drugs, the main objective is not specific targeting but maintaining adequate drug levels in the systemic circulation. Therefore, many oral formulations are developed as sustained-release systems to prolong therapeutic effects. By maintaining an adequate concentration of drug at the absorption site, the drug level in the bloodstream can be sustained for a longer period, which helps maintain effective drug concentration at the site of action.

In these systems, drug delivery generally involves three key steps: release of the drug from the dosage form, movement of the drug through the biological environment, and absorption across the epithelial membrane into the bloodstream. When toxicity is not a limiting factor, maintaining prolonged therapeutic levels can improve treatment effectiveness and reduce the frequency of dosing.

The design of sustained-release drug delivery systems depends on several physicochemical and biological factors, which influence drug release, absorption, and overall therapeutic performance.[35][36]

Oral Controlled Release Systems

Oral controlled release drug delivery systems are generally solid dosage forms designed to regulate the rate of drug release through dissolution, diffusion, or a combination of both mechanisms. Based on the pattern of drug release, these systems can be categorized as continuous release systems, where the drug is released gradually throughout the gastrointestinal tract during normal transit of the dosage form.

Continuous release systems include several approaches such as dissolution-controlled systems, diffusion-controlled systems, combined dissolution–diffusion systems, ion-exchange resin complexes, pH-dependent formulations, and osmotic pressure–controlled systems.

1. Dissolution-Controlled Release Systems

These systems are relatively simple to design and rely on controlling the rate at which the drug dissolves in gastrointestinal fluids. Some drugs naturally dissolve slowly (e.g., griseofulvin and digoxin), while others can be modified to dissolve slowly by forming less soluble compounds or by incorporating them into polymeric materials. In certain cases, drug particles are coated with polymers of varying thickness to reduce the dissolution rate.

Figure 3: Representation of dissolution controlled system

Types of Dissolution-Controlled Systems

Matrix (Monolithic) Systems:

In these systems, the drug is uniformly dispersed within a rate-controlling matrix. Materials such as beeswax or carnauba wax are commonly used to regulate the penetration of dissolution fluid and control drug release.

Reservoir Systems:

In reservoir systems, the drug core is surrounded by a coating made of slowly dissolving materials such as cellulose derivatives or polyethylene glycol. The thickness and solubility of the coating determine the rate of drug release.[36][[37]

2. Diffusion-Controlled Release Systems

In diffusion-controlled drug delivery systems, the release of the drug is regulated by its diffusion through a polymeric barrier. The dissolved drug moves through the polymer membrane or matrix, and this diffusion process acts as the rate-limiting step for drug release. As the drug continues to diffuse out, the path length for diffusion gradually increases, so the release rate typically decreases over time and does not follow a true zero-order pattern.

These systems are generally prepared in two ways: either by encapsulating the drug within a polymeric membrane (reservoir system) or by uniformly dispersing the drug within a polymer matrix (matrix system). In contrast to dissolution-controlled systems, drug release in diffusion-controlled formulations occurs mainly through partitioning and diffusion of the drug molecules across the polymer barrier.

Figure 4: Diffusion controlled release system

Diffusion-Controlled Systems

Diffusion-controlled drug delivery systems can be classified into reservoir type and matrix type systems.

Reservoir Type:

In reservoir systems, the drug core is surrounded by a polymeric coating or membrane. The drug particles are encapsulated using microencapsulation techniques with materials such as cellulose derivatives or polyethylene glycol. The rate of drug release depends mainly on the solubility and thickness of the polymer coating. In this system, the drug first partitions into the polymer membrane and then diffuses into the surrounding fluid.

Matrix Type:

In matrix systems, the drug is uniformly dispersed within an insoluble polymer matrix. Drug release occurs mainly by diffusion of the dissolved drug through the matrix, rather than by dissolution of the solid drug.

Overall, diffusion-controlled systems regulate drug release either by embedding the drug in an insoluble matrix or by coating the drug with a polymer membrane through which the drug diffuses gradually.

3. Dissolution and Diffusion Controlled Systems

In dissolution–diffusion controlled systems, the drug core is surrounded by a partially soluble membrane. When the dosage form comes in contact with gastrointestinal fluids, parts of the membrane dissolve and create pores. These pores allow the entry of the dissolution medium into the core, leading to drug dissolution. The dissolved drug then diffuses through the pores into the surrounding medium, thereby controlling the release rate.

4. Ion Exchange Resin Controlled Release

Ion exchange resins are cross-linked, water-insoluble polymers that contain ionizable functional groups. They are commonly used in pharmaceutical formulations for taste masking and controlled drug release. These resins can form complexes with ionizable drugs, and the drug is released when the complex comes in contact with suitable ions in the gastrointestinal fluids. The degree of cross-linking, diffusion path length, and surface area of the resin influence the drug release rate. Incorporation of ion exchange resins in polymeric matrices can modify and slow down the release of oppositely charged drugs due to the formation of drug–resin complexes.[38][39]

Figure 5 : Ion – exchange resin controlled system